Moleculin Biotech (MBRX) Free Cash Flow (2016 - 2025)
Moleculin Biotech (MBRX) posted quarterly Free Cash Flow of -$5.4 million for Q4 2025, down 5.57% year-over-year from -$5.7 million in Q4 2024, and up 25.71% quarter-over-quarter from -$7.2 million in Q3 2025.
Moleculin Biotech (MBRX) Free Cash Flow (2016 - 2025) Analysis & Trends
Moleculin Biotech's Free Cash Flow history runs 10 years deep, the most recent figure standing at -$5.4 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 5.57% year-over-year to -$5.4 million; the TTM figure through Dec 2025 stood at -$22.7 million (up 4.77% YoY), while the FY2025 annual figure was -$22.7 million, up 4.77% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$5.4 million, up from -$7.2 million in the prior quarter.
- The five-year high for Free Cash Flow was -$3.6 million in Q1 2021, with the low at -$8.1 million in Q2 2022.
- The 5-year median for Free Cash Flow is -$5.8 million (2024), against an average of -$5.9 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 76.7% in 2022, then jumped 36.27% in 2023.
- Moleculin Biotech's Free Cash Flow stood at -$4.3 million in 2021, then tumbled by 67.73% to -$7.3 million in 2022, then jumped by 31.39% to -$5.0 million in 2023, then slipped by 2.11% to -$5.1 million in 2024, then fell by 5.57% to -$5.4 million in 2025.
- Business Quant data shows MBRX's Free Cash Flow at -$5.4 million in Q4 2025, -$7.2 million in Q3 2025, and -$5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.37 Mn |
| Dec 31, 2025 | -5.37 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Mar 31, 2025 | -4.56 Mn |
| Mar 31, 2025 | -4.56 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Sep 30, 2024 | -6.11 Mn |
| Sep 30, 2024 | -6.11 Mn |
| Jun 30, 2024 | -5.96 Mn |
| Jun 30, 2024 | -5.96 Mn |
| Mar 31, 2024 | -6.72 Mn |
| Mar 31, 2024 | -6.72 Mn |
| Dec 31, 2023 | -4.98 Mn |
| Dec 31, 2023 | -4.98 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Sep 30, 2023 | -7.58 Mn |